Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications

Alexander Laarman; Fin Milder; Jos van Strijp; Suzan Rooijakkers

doi:10.1007/s00109-009-0572-y

Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications

Alexander Laarman, Fin Milder, Jos van Strijp, Suzan Rooijakkers

Research output: Contribution to journal › Review article › peer-review

Abstract

The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved different strategies to specifically impair the complement response. Here, we review the large arsenal of complement inhibitors produced by the gram-positive pathogens Staphylococcus aureus and Group A Streptococcus. We discuss how these bacterial molecules provide us with new tools to treat both infectious and inflammatory disease conditions in humans.

Original language	English
Pages (from-to)	115-20
Number of pages	6
Journal	Journal of molecular medicine (Berlin, Germany)
Volume	88
Issue number	2
DOIs	https://doi.org/10.1007/s00109-009-0572-y
Publication status	Published - 9 Jan 2010
Externally published	Yes

Keywords

bacterial proteins/genetics
complement activation/immunology
gram-positive bacteria/genetics
humans
immune evasion
staphylococcal infections/drug therapy
staphylococcus aureus/genetics
streptococcal infections/drug therapy
streptococcus pyogenes/genetics

Access to Document

10.1007/s00109-009-0572-yLicence: CC BY-NC

Cite this

@article{6dd82098031043e1a840ceb72a5bc94f,

title = "Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications",

abstract = "The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved different strategies to specifically impair the complement response. Here, we review the large arsenal of complement inhibitors produced by the gram-positive pathogens Staphylococcus aureus and Group A Streptococcus. We discuss how these bacterial molecules provide us with new tools to treat both infectious and inflammatory disease conditions in humans.",

keywords = "bacterial proteins/genetics, complement activation/immunology, gram-positive bacteria/genetics, humans, immune evasion, staphylococcal infections/drug therapy, staphylococcus aureus/genetics, streptococcal infections/drug therapy, streptococcus pyogenes/genetics, bacteri{\"e}le eiwitten/genetica, complementactivatie/immunologie, grampositieve bacteri{\"e}n/genetica, immuunontwijking, mensen, stafylokokkeninfecties/medicamenteuze behandeling, staphylococcus aureus/genetica, streptococcus pyogenes/genetica, streptokokkeninfecties/medicamenteuze behandeling",

author = "Alexander Laarman and Fin Milder and \{van Strijp\}, Jos and Suzan Rooijakkers",

year = "2010",

month = jan,

day = "9",

doi = "10.1007/s00109-009-0572-y",

language = "English",

volume = "88",

pages = "115--20",

journal = "Journal of molecular medicine (Berlin, Germany)",

issn = "0946-2716",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "2",

}

TY - JOUR

T1 - Complement inhibition by gram-positive pathogens

T2 - molecular mechanisms and therapeutic implications

AU - Laarman, Alexander

AU - Milder, Fin

AU - van Strijp, Jos

AU - Rooijakkers, Suzan

PY - 2010/1/9

Y1 - 2010/1/9

N2 - The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved different strategies to specifically impair the complement response. Here, we review the large arsenal of complement inhibitors produced by the gram-positive pathogens Staphylococcus aureus and Group A Streptococcus. We discuss how these bacterial molecules provide us with new tools to treat both infectious and inflammatory disease conditions in humans.

AB - The plasma proteins of the complement system are essential in the innate immune response against bacteria. Complement labels bacteria with opsonins to support phagocytosis and generates chemoattractants to attract phagocytes to the site of infection. In turn, bacterial human pathogens have evolved different strategies to specifically impair the complement response. Here, we review the large arsenal of complement inhibitors produced by the gram-positive pathogens Staphylococcus aureus and Group A Streptococcus. We discuss how these bacterial molecules provide us with new tools to treat both infectious and inflammatory disease conditions in humans.

KW - bacterial proteins/genetics

KW - complement activation/immunology

KW - gram-positive bacteria/genetics

KW - humans

KW - immune evasion

KW - staphylococcal infections/drug therapy

KW - staphylococcus aureus/genetics

KW - streptococcal infections/drug therapy

KW - streptococcus pyogenes/genetics

KW - bacteriële eiwitten/genetica

KW - complementactivatie/immunologie

KW - grampositieve bacteriën/genetica

KW - immuunontwijking

KW - mensen

KW - stafylokokkeninfecties/medicamenteuze behandeling

KW - staphylococcus aureus/genetica

KW - streptococcus pyogenes/genetica

KW - streptokokkeninfecties/medicamenteuze behandeling

U2 - 10.1007/s00109-009-0572-y

DO - 10.1007/s00109-009-0572-y

M3 - Review article

C2 - 20062962

SN - 0946-2716

VL - 88

SP - 115

EP - 120

JO - Journal of molecular medicine (Berlin, Germany)

JF - Journal of molecular medicine (Berlin, Germany)

IS - 2

ER -

Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications

Abstract

Keywords

Access to Document

Fingerprint

Cite this